New York, New York (PRWEB) July 21, 2013
Actos lawsuit claims involving allegations that the drug caused users to develop bladder cancer continue to move forward in a multidistrict litigation now underway in U.S District Court, Western District of Louisiana, Bernstein Liebhard LLP reports. According to court documents, the Actos bladder cancer litigation’s next Status Conference has been scheduled for Thursday, July 25th. An update issued by the U.S. Judicial Panel on Multidistrict Litigation on July 10th indicated that more than 2,400 Actos lawsuits are now pending in the consolidated proceeding. (In re: Actos Product Liability Litigation, MDL No. 2299)
“We continue to hear from individuals seeking to file Actos lawsuits that allege the drug caused their bladder cancer. We are pleased to see this litigation moving forward,” says Bernstein Liebhard LLP, nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos bladder cancer lawsuit evaluations to patients who developed the disease after using the medication for an extended period of time
Actos Bladder Cancer Lawsuits
Actos lawsuits pending in the Western District of Louisiana accuse Takeda Pharmaceuticals of concealing knowledge that use of the type 2 diabetes treatment was associated with an increased risk of bladder cancer, and failing to provide adequate warnings to patients and doctors regarding this risk. According to court documents, the first trial in the federal Actos litigation is scheduled to begin on January 27, 2014.
In April, the nation’s first trial involving Actos bladder cancer allegations ended with a Los Angeles Superior Court jury awarding $6.5 million to a plaintiff who was diagnosed with the disease after taking Actos for four years. However, the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)
Actos lawsuits have been mounting since June 2011, when the U.S. Food & Drug Administration (FDA) warned that use of Actos for one year or more had been linked to the development of bladder cancer.* According to Bloomberg.com, Actos was also pulled from the market in Germany and France that month because of its association with bladder cancer.**
Victims of bladder cancer allegedly associated with Actos may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please contact Bernstein Liebhard LLP today by calling 800-511-5092.
*fda.gov/drugs/drugsafety/ucm259150.htm, FDA, June 15, 2011
**bloomberg.com/news/2013-03-05/takeda-put-actos-sales-ahead-of-user-safety-witness-says.html, Bloomberg, March 5, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-bladder-cancer/prweb10947973.htm.
Copyright©2012 Vocus, Inc.
All rights reserved